509 related articles for article (PubMed ID: 23196570)
21. Molecular basis of amyotrophic lateral sclerosis.
Liscic RM; Breljak D
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):370-2. PubMed ID: 20655970
[TBL] [Abstract][Full Text] [Related]
22. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.
Hart MP; Gitler AD
J Neurosci; 2012 Jul; 32(27):9133-42. PubMed ID: 22764223
[TBL] [Abstract][Full Text] [Related]
23. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
Neumann M
Rev Neurol (Paris); 2013 Oct; 169(10):793-8. PubMed ID: 24011641
[TBL] [Abstract][Full Text] [Related]
24. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.
Lagier-Tourenne C; Polymenidou M; Cleveland DW
Hum Mol Genet; 2010 Apr; 19(R1):R46-64. PubMed ID: 20400460
[TBL] [Abstract][Full Text] [Related]
25. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS.
Sun Z; Diaz Z; Fang X; Hart MP; Chesi A; Shorter J; Gitler AD
PLoS Biol; 2011 Apr; 9(4):e1000614. PubMed ID: 21541367
[TBL] [Abstract][Full Text] [Related]
26. "STRESSED OUT": The role of FUS and TDP-43 in amyotrophic lateral sclerosis.
Aksoy YA; Deng W; Stoddart J; Chung R; Guillemin G; Cole NJ; Neely GG; Hesselson D
Int J Biochem Cell Biol; 2020 Sep; 126():105821. PubMed ID: 32758633
[TBL] [Abstract][Full Text] [Related]
27. Cytoplasmic functions of TDP-43 and FUS and their role in ALS.
Birsa N; Bentham MP; Fratta P
Semin Cell Dev Biol; 2020 Mar; 99():193-201. PubMed ID: 31132467
[TBL] [Abstract][Full Text] [Related]
28. FUS pathology in basophilic inclusion body disease.
Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
[TBL] [Abstract][Full Text] [Related]
29. Nuclear trafficking in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
Prpar Mihevc S; Darovic S; Kovanda A; Bajc Česnik A; Župunski V; Rogelj B
Brain; 2017 Jan; 140(1):13-26. PubMed ID: 27497493
[TBL] [Abstract][Full Text] [Related]
30. TDP-43 and FUS en route from the nucleus to the cytoplasm.
Ederle H; Dormann D
FEBS Lett; 2017 Jun; 591(11):1489-1507. PubMed ID: 28380257
[TBL] [Abstract][Full Text] [Related]
31. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration.
Nishimura AL; Zupunski V; Troakes C; Kathe C; Fratta P; Howell M; Gallo JM; Hortobágyi T; Shaw CE; Rogelj B
Brain; 2010 Jun; 133(Pt 6):1763-71. PubMed ID: 20472655
[TBL] [Abstract][Full Text] [Related]
32. Altered mRNP granule dynamics in FTLD pathogenesis.
Bowden HA; Dormann D
J Neurochem; 2016 Aug; 138 Suppl 1():112-33. PubMed ID: 26938019
[TBL] [Abstract][Full Text] [Related]
33. Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration.
Dormann D; Haass C
Mol Cell Neurosci; 2013 Sep; 56():475-86. PubMed ID: 23557964
[TBL] [Abstract][Full Text] [Related]
34. Different recognition modes of G-quadruplex RNA between two ALS/FTLD-linked proteins TDP-43 and FUS.
Ishiguro A; Katayama A; Ishihama A
FEBS Lett; 2021 Feb; 595(3):310-323. PubMed ID: 33269497
[TBL] [Abstract][Full Text] [Related]
35. Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS.
Suárez-Calvet M; Neumann M; Arzberger T; Abou-Ajram C; Funk E; Hartmann H; Edbauer D; Kremmer E; Göbl C; Resch M; Bourgeois B; Madl T; Reber S; Jutzi D; Ruepp MD; Mackenzie IR; Ansorge O; Dormann D; Haass C
Acta Neuropathol; 2016 Apr; 131(4):587-604. PubMed ID: 26895297
[TBL] [Abstract][Full Text] [Related]
36. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
[TBL] [Abstract][Full Text] [Related]
37. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?
van den Heuvel DM; Harschnitz O; van den Berg LH; Pasterkamp RJ
Trends Mol Med; 2014 Jan; 20(1):25-35. PubMed ID: 24140266
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD.
Shenouda M; Zhang AB; Weichert A; Robertson J
Adv Neurobiol; 2018; 20():239-263. PubMed ID: 29916022
[TBL] [Abstract][Full Text] [Related]
39. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia.
Mackenzie IR; Rademakers R; Neumann M
Lancet Neurol; 2010 Oct; 9(10):995-1007. PubMed ID: 20864052
[TBL] [Abstract][Full Text] [Related]
40. Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD.
Khosravi B; Hartmann H; May S; Möhl C; Ederle H; Michaelsen M; Schludi MH; Dormann D; Edbauer D
Hum Mol Genet; 2017 Feb; 26(4):790-800. PubMed ID: 28040728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
